A Milestone for Cholesterol Management
The U.S. Food and Drug Administration (FDA) has officially approved a new autoinjector version of Leqvio (inclisiran). This update marks an important step forward for patients who require ongoing management of high cholesterol and are looking for more convenient ways to administer their prescribed treatment.
Understanding the Update
Leqvio is a prescription medicine used alongside diet and statin therapy to help lower low-density lipoprotein (LDL-C) cholesterol in adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The approval of the autoinjector aims to simplify the delivery process for patients.
Key Details to Know
- Convenience: The new autoinjector is designed to be user-friendly, allowing for a more streamlined administration process.
- Consistent Care: The medication continues to be indicated as an adjunct to diet and maximally tolerated statin therapy.
- Professional Oversight: Patients should consult their healthcare provider to determine if the autoinjector is appropriate for their specific treatment plan and to receive proper training on its use.
As always, patients are encouraged to review the full prescribing information and discuss any questions or concerns regarding their cardiovascular health with their doctor. Always keep medications out of the reach of children and follow the storage instructions provided by your pharmacist.
Source: Read More